# Advisor Review - Advisor 2/3

**Role:** Academic advisor checking for fatal errors
**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** high
**Timestamp:** 2026-01-29T22:19:16.101191
**Response ID:** resp_0ded768301ae68a400697bcd98dfc88195b7cb18bc2a8af384
**Tokens:** 41180 in / 6304 out
**Response SHA256:** 59cfa9fbdbcacf1a

---

No fatal errors found in the four required categories. I checked (i) treatment timing against outcome-data coverage, (ii) existence of post-treatment observations by cohort, (iii) internal consistency of the “full-exposure year” treatment definition across the text/tables/figures, (iv) numerical sanity of coefficients/SEs/CIs in every reported results table, and (v) completeness (no placeholders; key tables report N and uncertainty).

### 1) DATA–DESIGN ALIGNMENT (CRITICAL): OK
- **Treatment timing vs data coverage:** Maximum “full-exposure year” is **2021** (ID, WY in Table 2), and outcome data run through **2023** (LAUS 2007–2023). So **max(treatment year) ≤ max(data year)** holds.
- **Post-treatment observations exist for each cohort:**  
  - 2013 cohort has post 2013–2023; 2021 cohort has post 2021–2023 (3 years).  
  - No cohort is “treated” without any post-treatment outcomes in the main LAUS analysis.
- **Treatment definition consistency:** The “full-exposure year” convention described in Section 3.2 matches Table 2 and is carried consistently into the CS event-time definitions and figures. The use of **anticipation = 1** is consistent with your stated goal of handling transition-year partial exposure.

### 2) REGRESSION SANITY (CRITICAL): OK
Across all displayed results tables (Tables 3–20):
- No impossible values (no NaN/Inf/NA; no negative SEs).
- No implausibly huge coefficients for log outcomes (all are small in magnitude).
- No SEs that are obviously collinearity artifacts (nothing remotely near the “SE > 1000” or “SE > 100×|coef|” type failures for these outcomes).
- Confidence intervals and p-values shown in text are numerically consistent with the reported coefficient/SE pairs in the main results (e.g., Table 3).

### 3) COMPLETENESS (CRITICAL): OK
- No placeholders (“TBD”, “TODO”, etc.) in tables/figures shown.
- Main regression table (Table 3) reports **N**, states, treatment/control descriptions, and **standard errors**.
- Methods described (CS-DiD, TWFE, event studies, placebo, pre-COVID subsample, Bacon decomposition, first-stage check) have corresponding reported outputs/tables/figures in the draft.

### 4) INTERNAL CONSISTENCY (CRITICAL): OK
- Cohort counts by adoption year in the text match Table 2 (3, 3, 4, 6, 5, 9, 12, 2, 2 = 46).
- The narrative about the thin never-treated control group (4 states) matches the tables/figures that use that group.
- The event-study interpretation (“uniform bands include zero” for pre-trends under not-yet-treated) matches the uniform CIs shown (e.g., Table 7).

ADVISOR VERDICT: PASS